GenVec Inc

Type: Company

Name: GenVec Inc

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Shares Declining Update: GNVC, SBLK, RCON, DRWI

Equitymarketreport.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace ... [Published SBWire - May 14 2013]

Entities: Star Bulk Carriers Corp, DragonWave Inc, Recon Technology Ltd, GenVec Inc, Stocks

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Theravance Inc

Notable 52-Week Highs and Lows of the Day 05/13: (TSLA) (THRX) (FSLR) High; (GNVC) (ANV) Low

Tesla Motors, Inc. (Nasdaq: TSLA) $86.98. Tesla up over 13 percent today as shares keep ramping higher. No news out today, but CEO Elon Musk and crew are expected to make an announcement in the Supercharger system later this week.Theravance, Inc. (Nasdaq: ... [Published Street Insider - May 13 2013]

Entities: Theravance Inc, Ellipta, Maba (China), Élan Corporation plc, GenVec Inc

First reported May 13 2013 - Updated May 13 2013 - 1 reports

GenVec Inc

IT's Monday and Stocks to Eyes on (EMKR, GNVC, TSEM, CIMT)

New York, NY -- (SBWIRE) -- 05/13/2013 -- EMCORE Corporation (NASDAQ:EMKR) traded down 6.94% Monday to $3.38.The Company released second quarter results. Consolidated revenue for the second quarter ended March 31, 2013 was $42.3 million.Consolidated ... [Published SBWire - May 13 2013]

Entities: GenVec Inc, Stocks, Net Profit

First reported May 13 2013 - Updated May 13 2013 - 1 reports

EMCORE Corp

Stocks Hitting 52-Week Lows

Today 11:17 AM ET (Benzinga)SI Financial Group Inc. (NASDAQ: SIFI) shares lost 0.79% to create a new 52-week low of $10.72. SI Financial Group has a trailing twelve month loss margin of 1.97%.GenVec, Inc. (NASDAQ: GNVC) shares fell 29.40% to touch a new ... [Published TD Ameritrade - May 13 2013]

Entities: GenVec Inc, SI Financial Group Inc, EMCORE Corp

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Kubota Corp

Mid-Morning Market Update: April Retail Sales Beat Expectations, Business Inventories for March Show a Decline

Following the market opening Monday, the Dow traded down 0.26 percent to 15,079.29, while the NASDAQ diped 0.10 percent to reach 3,433.12. The S&P also fell, declining 0.20 percent to 1,630.41.Top HeadlineThe US Commerce Department reported retail sales ... [Published Benzinga.com - May 13 2013]

Entities: Retail Sales, Kubota Corp, Theravance Inc, Platinum Group Metals Ltd, National Bank of Greece SA

First reported May 11 2013 - Updated May 11 2013 - 1 reports

GENVEC INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GenVec, Inc. (GenVec, we, our, or the Company) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates ... [Published Pharmacy Choice - May 11 2013]

Entities: GenVec Inc, Vaccine, Malaria, Animal Health

First reported May 09 2013 - Updated May 09 2013 - 1 reports

ResearchMoz.us: Angiogenesis Inhibitors and Stimulators Market: Global Trends and Forecast 2012-2018

The process of formation of new blood vessel from the existing blood vessel by intussusceptive or budding is termed as Angiogenesis. And hence it places a crucial role in growth and renewal of body tissues in order to maintain wear and tear of the body ... [Published MyNewsDesk - May 09 2013]

Entities: angiogenesis, Market, Celltech Group plc, OSI Pharmaceuticals Inc

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Investigators from GenVec Zero in on Neuroepithelial Cells

By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Sensory Receptor Cells is the subject of a report. According to news originating from Gaithersburg, Maryland, by NewsRx correspondents, research stated, "To evaluate the ... [Published Equities.com - May 08 2013]

Entities: Hair Cell, GenVec Inc, Furosemide, Kanamycin

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

GenVec CEO Discusses Q4 2012 Results - Earnings Call Transcript

GenVec ( GNVC ) Q4 2012 Earnings Results March 22, 2013 10:00 AM ET Executives Douglas Swirsky - SVP & CFO Cindy Collins - President & CEO Analysts Joe Pantginis - Roth Capital Presentation Operator Good morning ladies and gentlemen, ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 22 2013]

Entities: GenVec Inc, Cindy Collins, Roth Capital Partners

Quotes

According to the news editors, the research concluded: "Ad28.gfap.atoh1 promotes hair cell regeneration in cochlea ablated with kanamycin and furosemide resulting in moderate hearing recovery."

Investigators from GenVec Zero in on Neuroepithelial Cells [Published Equities.com - May 08 2013]

...Executive Chairman of BDSI. "Tom's significant industry experience and leadership, which spans over more than 30 years in both large pharmaceutical and smaller biotechnology companies, will be a tremendous asset to BDSI."

BioDelivery Sciences International (BDSI) Appoints Thomas W. D'Alonzo to Board of Directors [Published FierceBiotech - May 03 2013]

"This is an area that's a bit more futuristic and ultimately restoring the hair cells will be the cure."

Drugmakers Step Up Search For Hearing Loss Medicines [Published The Huffington Post | Full News Feed - Dec 03 2012]

More Content

sort by: Date \| Relevance
Shares Declining Update: GNVC, SBLK, RCON, DRWI [Published SBWire - May 14 2013]
Unusual 11 Mid-Day Movers 05/13: (PNTR) (TGX) (... [Published Street Insider - May 13 2013]
Notable 52-Week Highs and Lows of the Day 05/13... [Published Street Insider - May 13 2013]
IT's Monday and Stocks to Eyes on (EMKR, GNVC, ... [Published SBWire - May 13 2013]
Stocks Hitting 52-Week Lows [Published TD Ameritrade - May 13 2013]
Mid-Morning Market Update: April Retail Sales B... [Published Benzinga.com - May 13 2013]
GENVEC INC - 10-Q - MANAGEMENT'S DISCUSSION AND... [Published Pharmacy Choice - May 11 2013]
ResearchMoz.us: Angiogenesis Inhibitors and Sti... [Published MyNewsDesk - May 09 2013]
Investigators from GenVec Zero in on Neuroepith... [Published Equities.com - May 08 2013]
BioDelivery Sciences International (BDSI) Appoi... [Published FierceBiotech - May 03 2013]
BioDelivery Sciences International (BDSI) Appoi... [Published BioSpace - Apr 29 2013]
BioDelivery Sciences International Appoints to ... [Published BioSpace - Apr 29 2013]
BioDelivery Sciences Appoints Thomas W. DAlonzo... [Published Equities.com - Apr 29 2013]
BioDelivery Sciences Appoints Thomas W. D'Alonz... [Published FinanzNachrichten.de - Apr 29 2013]
Research and Markets: Respiratory Syncytial Vir... [Published Business Wire - Apr 17 2013]
Respiratory Syncytial Virus (RSV) Infections - ... [Published PredictWallStreet - Apr 17 2013]
GenVec CEO Discusses Q4 2012 Results - Earnings... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 22 2013]
GenVec Reports Fourth Quarter And 2012 Year-End... [Published Financial Services - Mar 22 2013]
GenVec To Release Fourth Quarter And Year-end 2... [Published Financial Services - Mar 15 2013]
GenVec to Present at 25th Annual ROTH Conference [Published PR Newswire: Health - Mar 12 2013]
GenVec President & CEO Cynthia Collins Joins Bi... [Published PR Newswire: Health - Feb 11 2013]
Single Administration of GenVec's Vaccine Provi... [Published PR Newswire: Health - Dec 17 2012]
Drugmakers Step Up Search For Hearing Loss Medi... [Published The Huffington Post \| Full News Feed - Dec 03 2012]
GenVec inks contract agreement with Naval Medic... [Published PharmaBiz - Oct 04 2012]
GenVec Enters Into $3.5 Million Contract With N... [Published PR Newswire - Oct 02 2012]
8-K - GENVEC INC (0000934473) (Filer) [Published SEC Filings - Sep 25 2012]
Biography for Wayne Hockmeyer [Published Able2Act - Oct 04 2007]